Medical systems distributer, SmartMed, a subsidiary of Healthxchange Group, has introduced the Envy Facial to its product portfolio.
The Envy Facial is a skin resurfacing treatment that simultaneously combines exfoliation, extraction and the infusion of condition-rich serums.
According to the company, the treatment drives serums deep into the epidermal layers at the exact point of exfoliation and extraction to ensure maximum penetration of actives at optimal depths within the skin for enhanced absorption.
The facial aims to improve skin radiance, visibly reduce fine lines and wrinkles and stimulate healthy cell renewal.
“A big focus for me this year has been skin rejuvenation. Many people know me for my work with toxin and filler, particularly lip augmentation, but skin plays a major role in my patient journey,” aesthetic practitioner Dr Tijion Esho said.
He added, “For both of my clinic sites I researched the best lasers, peels and microneedling devices and incorporated them into my clinics, but I still felt that there was a small gap in my repertoire for treatments that gave instant and progressive results with minimal downtime. The Envy Facial filled the gap perfectly! It’s compact, sleek and easy to use with a variety of options and most importantly, it really works! I loved it and I can’t wait for my patients to have the Envy experience.”
Steve Joyce, marketing and technology director at Healthxchange Group commented, “We are committed to providing the most effective treatments and products. The launch of Envy Facial fills a gap in the market by providing patented three-in-one technology, which delivers the penetration of active ingredients at optimal skin depths. This has quickly become a celebrity favourite and we look forward to welcoming practitioners to the upcoming live demonstrations so they too can become the ‘Envy of aesthetics’.”
Live Envy Facial demonstrations will be taking place in London on February 20 at the Cavendish Conference Centre and in Manchester on February 21 at the Healthxchange Academy.